An Open-Label Phase Ib/II Study of Avelumab in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Avelumab (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2021 Results (data cutoff date June 1, 2020) assessing safety and efficacy of azacitidine with avelumab in patients with relapsed/refractory acute myeloid leukemia, published in the Cancer.
- 23 Jan 2020 Status changed from active, no longer recruiting to discontinued.
- 06 Nov 2019 Results (n=9) characterising immune profiling from relapsed/refractory acute myeloid leukemia patients undergoing therapy with azacitidine and avelumab, released in 61st Annual Meeting and Exposition of the American Society of Hematology